Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

APOLLO Success Clears Alnylam For Lift-Off

Sep 20 2017

• By Joseph Haas

train fast run on railway track in sunny day

Related Content

Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work

Dec 21 2015

Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic

Oct 06 2016

Alnylam Hopes To Resume Fitusiran Dosing Quickly, Despite Unclear Cause Of Trial Death

Sep 07 2017

Ionis Touts Inotersen's Convenience As Phase III Safety Data Disappoints

May 16 2017

Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings

Apr 26 2017

Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line

Aug 11 2017

Related Companies

Alnylam Pharmaceuticals Inc.

Sanofi

Ionis Pharmaceuticals, Inc.

GSK plc

Additional Topics

Clinical Trials Drug Safety Platform Technologies Business Strategies Commercial Rare Diseases Research & Development BioPharmaceutical Metabolic Disorders

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window